Premium
Evaluation of resting state gamma power as a response marker in schizophrenia
Author(s) -
Mitra Sayantanava,
Nizamie S. Haque,
Goyal Nishant,
Tikka Sai Krishna
Publication year - 2015
Publication title -
psychiatry and clinical neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 74
eISSN - 1440-1819
pISSN - 1323-1316
DOI - 10.1111/pcn.12301
Subject(s) - electroencephalography , schizophrenia (object oriented programming) , antipsychotic , audiology , psychology , medicine , neuroscience , psychiatry
Aims An abnormal activity in the electroencephalography ( EEG ) gamma band (>30 Hz) has been demonstrated in schizophrenia and this has been suggested to be reflecting a deficit in the development and maturation of the basic cognitive functions of attention, working memory and sensory processing. Hypothesizing gamma oscillatory activity as a potential EEG biomarker to antipsychotic response in schizophrenia, the present study aimed at measuring baseline spontaneous gamma activity in schizophrenia patients, and evaluating its response to antipsychotic treatment over 8 weeks. Methods Fifteen drug‐free/naïve patients were recruited, compared at baseline with 15 age‐, sex‐ and education‐matched healthy controls, and were followed up for 8 weeks' treatment on antipsychotics. Resting state EEG waves were recorded using high (192‐channel) resolution EEG at admission, 4 weeks and 8 weeks. Spectral power was calculated using fast F ourier transformation, H anning window. The power was averaged region‐wise over nine regions in three frequency ranges (30–50 Hz, 50–70 Hz, 70–100 Hz). Results Patients and controls differed significantly at intake in terms of left temporal and parietal high (70–100 Hz) gamma power. Consequently, no significant differences were seen over the course of antipsychotic treatment on gamma spectral power in any of the regions. Conclusions Lack of significant effect of treatment on gamma power suggests that these gamma oscillations may be trait markers in schizophrenia.